Novo’s $165m REPAIR fund seeks to support projects from LO to Phase 1

Dear All:

Just announced today (press releasewebsite), Novo Holdings has created a $165m impact fund that seeks to support novel therapies from Lead Optimization (LO) through Phase 1. The fund specifically targets “first-in-class therapies, covering small molecules, biologics, and new modalities.” Similar to the focus of CARB-X, REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) will focus on priority pathogens from the CDC and WHO priority lists. 

The origin of the idea for this project appears to be from social impact goals of the Novo Nordisk Foundation: “The vision of the Foundation is to contribute significantly to research and development that improves the health and welfare of people. The Foundation donates about $300-600 million per year primarily for medical research.”

A first round of investments dedicated to European companies will start in April 2018 (non-confidential presentations can be sent until 15 May 2018) and is expected to lead to investments by the end of 2018. A second round of investments focusing on United States companies will start in the fall 2018.

All told, the fund expects to invest USD 20-40 million per year over 3–5 years in about 20 projects in Europe and the United States. The overall goal is at least one new therapy reaching the market.

It’s exciting to see this additional source of push funding! Although funds from REPAIR are presumably dilutive in nature (rather than the non-dilutive financing of CARB-X), the availability of funds from a group who understand the challenge and opportunity of antimicrobial resistance will be a powerful new force for progress. Thank you, Team Novo!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future:

Upcoming meetings of interest to the AMR community:


Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top